Next clinical milestone for Vyvgart Hytrulo by end of 2024? | Categorical | | | 6 months ago | |
Argenx stock price performance by end of 2024? | Categorical | | | 6 months ago | |
Vyvgart Hytrulo EMA approval for CIDP by end of 2024? | Binary | | | 6 months ago | |
Vyvgart Hytrulo sales exceed $500M by end of 2024? | Binary | | | 6 months ago | |
Vyvgart Hytrulo FDA recall by end of 2024? | Binary | | | 6 months ago | |
Vyvgart Hytrulo market share in CIDP by end of 2024? | Categorical | | | 6 months ago | |
Outcome of Halozyme's Proposed Acquisition of Evotec by End of 2025? | Categorical | | | 1 month ago | |
Evotec Stock Price Exceeds €11 per Share by End of 2024? | Binary | | | 1 month ago | |
Halozyme's Acquisition of Evotec at €11 per Share by June 30, 2025? | Binary | | | 1 month ago | |
Will Genentech's stock price increase by at least 10% by the end of 2024? | Binary | | | 3 months ago | |
Will Halozyme's stock price increase by at least 15% by the end of 2024? | Binary | | | 3 months ago | |
Regulatory Hurdles for Halozyme's Acquisition of Evotec by End of 2025? | Binary | | | 1 month ago | |
Counteroffer for Evotec Acquisition by March 31, 2025? | Categorical | | | 1 month ago | |
Primary Reason for Outcome of Halozyme's Acquisition Attempt by End of 2025? | Categorical | | | 1 month ago | |
How many additional indications will Tecentriq Hybreza receive FDA approval for by the end of 2025? | Categorical | | | 3 months ago | |
Will Tecentriq Hybreza become the leading treatment for non-small cell lung cancer by market share in the US by mid-2025? | Binary | | | 3 months ago | |
How many patients will be treated with Tecentriq Hybreza in the US by the end of Q1 2025? | Categorical | | | 3 months ago | |
Which cancer immunotherapy will gain the most market share in the US by the end of 2024? | Categorical | | | 3 months ago | |
